Antihypertensive treatment in masked hypertension for target organ protection (ANTI-MASK): a randomized, double-blind, placebo-controlled trial

Blood Press Monit. 2022 Dec 1;27(Suppl 1):e3. doi: 10.1097/01.mbp.0000905172.14581.d1. Epub 2022 Nov 25.

Authors

Jian-Feng Huang¹, Ming-Xuan Li¹, Dong-Yan Zhang¹, De-Wei An¹, Xin Chen¹, Ying-Qing Feng², Qi-Dong Zheng³, Yan Li¹, Ji-Guang Wang¹

Affiliations

¹ Department of Cardiovascular Medicine, Shanghai Institute of Hypertension, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
² Department of Cardiology, Guangdong Provincial Peoples' Hospital, Guangzhou, Guangdong, China.
³ Department of Internal Medicine, Yuhuan 2 Peoples' Hospital, Taizhou, Zhejiang, China.

PMID: 36445420
DOI: 10.1097/01.mbp.0000905172.14581.d1

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Antihypertensive Agents / therapeutic use
Blood Pressure
Humans
Masked Hypertension* / diagnosis
Masked Hypertension* / drug therapy

Substances

Antihypertensive Agents